Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786915 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days
A Phase 1 study, sponsored by Stealth BioTherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01786915 is a Phase 1 study that has completed, run by Stealth BioTherapeutics. The registered enrollment target is 30 participants.
The verdict
NCT01786915, a Phase 1 study, has completed, sponsored by Stealth BioTherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.
Interventions
- DRUG Placebo
- DRUG Bendavia 10mg
- DRUG Bendavia 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786915
The ClinicalTrials.gov registry entry for NCT01786915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01786915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01786915 about?
NCT01786915 is a clinical study titled "Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days". The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.
What is the current status of trial NCT01786915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01786915?
The interventions under investigation include: Placebo (DRUG), Bendavia 10mg (DRUG), Bendavia 50mg (DRUG).
Who is sponsoring clinical trial NCT01786915?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.